FILTER BY TOPIC
Dr. David T. Rubin discusses evaluating and treating patients with IBD in his practice.
Education, disease management, and more form part of comprehensive IBD treatment.
Current topics of research in IBD include disease severity and duration at initiation of treatment, and the burden of suboptimal therapy.
Lymphocyte trafficking to the gut involves a multistep adhesion cascade process.
Treat-to-target as a strategy combines regular assessment of disease activity with a protocol in which therapeutic consequences and targets are predefined.
Gain access to members-only content and downloadable resources about IBD.
IBD is associated with substantial physical and emotional burdens for patients.
Efficacy, safety, and patient response are some of the key considerations when reviewing IBD treatment options.
Key IBD management goals continue to change to better address long-term disease progression and outcomes.
While the causes of IBD are unknown, several studies have suggested a variety of hypotheses.
Defects in normal gut immunity may contribute inappropriate inflammatory responses characteristic of IBD.
IBD is a global phenomenon, affecting a significant proportion of the population in the Americas and Europe, as well as Africa and Asia.
The normal GI tract is a tightly controlled environment designed to elicit appropriate immune responses.
UC and CD share several clinical features, characterized by chronic GI tract inflammation.
The worldwide public health burden of IBD, including economic costs, is estimated to be billions of dollars yearly.
+ Show references